Advancing Science.
Improving Connections.
Next-Generation Transdermal
Cannabinoid Therapeutics
NASDAQ | June 2022 |
ZYNE
© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved.
Forward-Looking Statements
The statements in this presentation may include forward-looking statements within the meaning of the private securities litigation reform act of 1995. These statements, among other things relate to the future operations, opportunities or financial performance of Zynerba pharmaceuticals, inc. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations, including the following: the company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the results, cost and timing of the company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; clinical results for the company's product candidates may not be replicated or continue to occur in the company's ongoing or planned clinical trials in FXS, 22q, or ASD, or in any additional trials, and may not otherwise support further development in a specified indication or at all; the company's
planned reconnect trial may not be determined to be sufficient to support a submission for regulatory approval, including an nda or maa; actions or advice of the U.S. Food and drug administration and foreign regulatory agencies may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the company's ability to obtain and maintain regulatory approval for its product candidates, and the labeling under any such approval; the company's expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates. These and other risks are described in our filings with the securities and exchange commission, available at www.sec.gov. Any forward-looking statements that the company makes in this presentation speak only as of the date of this presentation. The company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this presentation.
© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners.
2 | Zynerba Pharmaceuticals | Advancing Science. Improving Connections. | June 2022 | |
A different and exciting
approach to Cannabidiol
An Orphan-Focused Neuropsychiatric, Biopharmaceutical Company
FIRST AND ONLY | LATE-STAGE |
TRANSDERMAL | |
PIPELINE | |
CANNABIDIOL GEL | |
Permeation-enhanced | One Phase 3 clinical | |
program ongoing | ||
Patent-protected | ||
through 2038 | Two additional | |
indications are Phase 3 | ||
Pharmaceutically | ready | |
manufactured; THC free | ||
POSITIONED FOR SUCCESS
Leadership expertise in transdermal delivery, rare diseases and specialty markets
Clean balance sheet and cash runway to end of 2023 / early 2024
A different and exciting approach to Cannabidiol
4 | Zynerba Pharmaceuticals | Advancing Science. Improving Connections. | June 2022 | |
Benefits of Our Approach to Cannabidiol
PHARMACEUTICAL MANUFACTURING
FDA regulated
Consistency of production
Purity of ingredients
No THC - not a scheduled drug by U.S. DEA
Scalable production process
TRANSDERMAL DELIVERY
Ease of application for caregivers of patients with behavioral issues
Minimizes GI side effects and reduces risk for liver toxicity
Lower risk for drug/drug interactions
Avoids conversion to THC in stomach
5 | Zynerba Pharmaceuticals | Advancing Science. Improving Connections. | June 2022 | |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Zynerba Pharmaceuticals Inc. published this content on 22 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2022 13:04:03 UTC.